ProShare Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-28,146
Closed -$130K 1674
2019
Q1
$130K Buy
28,146
+137
+0.5% +$649 ﹤0.01% 1546
2018
Q4
$98K Sell
28,009
-5,558
-17% -$38.6K ﹤0.01% 1475
2018
Q3
$338K Sell
33,567
-994
-3% -$7.93K ﹤0.01% 1291
2018
Q2
$250K Sell
34,561
-2,458
-7% -$17.1K ﹤0.01% 1489
2018
Q1
$224K Sell
37,019
-6,047
-14% -$49.9K ﹤0.01% 1488
2017
Q4
$414K Buy
43,066
+470
+1% +$3.08K ﹤0.01% 1232
2017
Q3
$378K Buy
42,596
+3,451
+9% +$35.6K ﹤0.01% 1068
2017
Q2
$495K Sell
39,145
-1,864
-5% -$22.1K ﹤0.01% 970
2017
Q1
$431K Sell
41,009
-10,179
-20% -$108K ﹤0.01% 1064
2016
Q4
$471K Buy
51,188
+3,713
+8% +$41.9K 0.01% 1109
2016
Q3
$560K Sell
47,475
-8,661
-15% -$132K 0.01% 904
2016
Q2
$726K Buy
56,136
+331
+0.6% +$4.82K 0.01% 821
2016
Q1
$892K Sell
55,805
-5,548
-9% -$105K 0.01% 741
2015
Q4
$1.76M Buy
61,353
+4,305
+8% +$119K 0.02% 550
2015
Q3
$1.62M Sell
57,048
-2,993
-5% -$110K 0.02% 531
2015
Q2
$2.16M Sell
60,041
-147
-0.2% -$4.58K 0.03% 490
2015
Q1
$1.75M Buy
60,188
+9,596
+19% +$254K 0.02% 604
2014
Q4
$1.07M Buy
50,592
+7,098
+16% +$140K 0.01% 821
2014
Q3
$843K Sell
43,494
-7,806
-15% -$123K 0.01% 1132
2014
Q2
$801K Sell
51,300
-13,414
-21% -$217K 0.01% 1272
2014
Q1
$1.34M Buy
64,714
+35,329
+120% +$701K 0.02% 1053
2013
Q4
$379K Buy
+29,385
New +$408K 0.01% 1110

Other funds holding INSY

ProShare Advisors's INSY Position: Q2 2019 in Review

ProShare Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 28,146 shares — an estimated $130K sold.

ProShare Advisors first reported a position in INSY in Q4 2013 and held it in 22 quarters. The position peaked at $2.16M in Q2 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • ProShare Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • ProShare Advisors sold 28,146 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $130K.
  • ProShare Advisors first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 22 quarters.
  • ProShare Advisors's Insys Therapeutics, Inc. position peaked at $2.16M in Q2 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on ProShare Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.